External beam radiotherapy for prostate cancer

Panminerva Medica

Volumn 52, Issue 3, 2010, Pages 195-207

  Pinkawa, M ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Adjuvant; Computer assisted Radiotherapy; Prostatic neoplasms Radiotherapy Radiotherapy dosage Radiotherapy

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; PROSTATE TUMOR; PROSTATECTOMY; RADIATION DOSE;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952066344     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Schwartz RS. Management of prostate cancer-polling results. N Engl J Med 2009;360:e4.
2. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
3. Bolla M, Van PH, Collette L, van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8. (Pubitemid 41140332)
4. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: longterm followup of a randomized clinical trial. J Urol 2009; 181:956-62.
5. Wiegel T, Bottke D, Steiner U, Siegmann A, GoIz R, Störkel S et al. Phase III postoperative adjuvant tadiotherapy after radical prostatectomy compared with radical prostatectomy in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 9602/AUO AP 09/95. J Clin Oncol 2009; 18:2924-30.
6. Roach M, III, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH et al. Defining biochemical failure follwing radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
7. ASTRO Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
8. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D et al. Comparison of radiation side-effects of conformai and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72.
9. Koper PC, Jansen P, van Putten W, van Os M, Wijnmaalen AJ, Lebesque JV et al. Gastro-intestinal and genito-urinary morbidity after 3D conformai radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 2004;73:1-9. (Pubitemid 39304119)
10. Zhang P, Happersett L, Hunt M, Jackson A, Zelefsky M, Mageras G. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys 2010;76:1456-62.
11. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008;72:799-807.
12. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of the dose distribution with and without 18Fcholine PET-CT detected simultaneous integrated boost. Radiother Oncol2009;93:213-9.
13. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformai therapy planning. Int J Radiat Oncol Biol Phys 2002;53:595-9. (Pubitemid 34626498)
14. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000;89:1800-9.
15. 1H MR spectroscopic imaging - correlation with pathologic findings. Radiology 2008;246:480-8.
16. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D et al. Imaging prostate cancer with 11 C-choline PET/CT. J Nucl Med 2006;47:1249-54. (Pubitemid 47544875)
17. Pinkawa M, Piroth MD, Holy R, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline pet-ct to define a simultaneous integrated boost. Radiother Oncol2010;94:Sll.
18. Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z. Whole pelvic radiotherapy for prostate cancer using 3D conformai and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:765-71. (Pubitemid 41400064)
19. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9. (Pubitemid 44307191)
20. Pinkawa M, Siluschek J, Gagel B, Demirel C, Asadpour B, Holy R et al. Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer. Radiother Oncol 2006;81:284-90. (Pubitemid 44856007)
21. de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD er al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:965-73.
22. Nederveen AJ, Dehnad H, van der Heide UA, van Moorselaar RJ, Hofman P, Lagendijk JJ. Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials. Radiother Oncol 2003;68:81-8. (Pubitemid 37289340)
23. Paskalev K, Ma CM, Jacob R, Price R, McNeeley S, Wang L et al. Daily target localization for prostate patients based on 3D image correlation. Phys Med Biol 2004;49:939.
24. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J et al. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction motion. Strahlenther Onkol 2008; 184:679-85.
25. Beckendorf V Guerif S, Le Prise E, et al. 70 Gy versus 80Gy dose escalation getug 06 french trial for localized prostate cancer: mature results. Int J Radiat Oncol Biol Phys 2008;72:S96-S97.
26. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR et al Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
27. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J ClinOncol 2006;24:1990-6. (Pubitemid 46622106)
28. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA et al. Comparison of conventional-dose vs.high-dose radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005;294:1233-9. (Pubitemid 41352111)
29. Kuban DA, Levy LB, Tucker SL, et al. Long-term patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of the disease? Int J Radiat Oncol Biol Phys 2008;72:S93.
30. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Diel wart MF, Incrocci L et al. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980-8.
31. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ et al. Randomized trial comparing conventional-dose with high-dose conformai radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28:1106-11.
32. Viani GA, Stefano EJ, Alfonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
33. Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Borchers H et al. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (1-125) brachytherapy for prostate cancer. Radiotherapy and Oncology 2010 [Epub ahead of print].
34. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L; ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-21.
35. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84:114-20. (Pubitemid 47284526)
36. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in nodenegative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-9. (Pubitemid 46202276)
37. Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G et al. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology 2007;69:129-33. (Pubitemid 46161683)
38. Gluck I, Vineberg KA, Ten Haken RK, Sandler HM. Evaluating the relationship between rectal normal tissue complication probability and the portion of seminal vesicles included in the clinical target volume in intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:334-40.
39. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:29-37. (Pubitemid 46803038)
40. Cozzarini C, Bolognesi A, Ceresoli GL, Fiorino C, Rossa A, Bertini R et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 2004;59:674-83. (Pubitemid 38748732)
41. Zagars GK, Pollack A, Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically nodepositive prostate cancer. Urology 2001 ;58:233-9. (Pubitemid 32728063)
42. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006;66:647-53.
43. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randmised trial. Lancet 2002;360:103-8. (Pubitemid 34786197)
44. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movias B et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90. (Pubitemid 40470408)
45. Lilleby W, Dale E, Olsen DR, Gude U, Fossa SD. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta Oncol 2003;42:10-4. (Pubitemid 36307879)
46. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997;49:38-45. (Pubitemid 27133509)
47. See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006; 132(Suppl 1 ):S7-16.
48. Pilepich M, Winter K, John MJ, Mesic JB, Sause W, Rubin P et al. Phase III radiation therapy oncology group (rtog) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001 ;50:1243-52. (Pubitemid 32727802)
49. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7. (Pubitemid 39079668)
50. Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADR -results of a randomized eortc phase III trial 22961. J Clin Oncol 2007;25:5014.
51. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8. (Pubitemid 46606211)
52. Souhami L, Bae K, Pilepich M, Sandler HM. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer: a secondary analysis of rtog 85-31. J Clin Oncol 2009;27:2143.
53. Higano C, Shields A, Wood N. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182-6. (Pubitemid 39647063)
54. Smith MR. Changes in fat and lean body during androgen-deprivation therapy for prostate cancer. Urology 2004;63:742-5. (Pubitemid 38479421)
55. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51:306-14. (Pubitemid 44937805)
56. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. (Pubitemid 27318990)
57. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with threedimensional conformai radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:397-405. (Pubitemid 40704456)
58. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3-11.
59. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G et al. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology 2006;68:104-9. (Pubitemid 44037735)
60. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nüssen S et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83-9. (Pubitemid 350251028)
61. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004;60:1013-5. (Pubitemid 39440782)
62. Akimoto T, Muramatsu H, Takahashi M, Saito J, Kitamoto Y, Harashima K et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys 2004;60:1033-9. (Pubitemid 39440786)
63. Goldner G, Tomicek B, Becker G, Geinitz H, Wachter S, Zimmermann F et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 2007;67:78-83. (Pubitemid 44959504)
64. Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R et al. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer-predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol 2009;4:36.
65. Yeoh EK, Holloway RH, Fraser RJ, Borten R, Di Matteo A, Moore JW et al. Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostata. Int J Radiat Oncol Biol Phys 2009;73:46-52.
66. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, EbIe MJ et al. Low-grade toxicity after conformai radiation therapy for prostate cancer-impact of bladder volume. Int J Radiat Oncol Biol Phys 2006;64:835-41. (Pubitemid 43183582)
67. Zelefsky MJ, Wallner KE, Ling CC. Comparison of the 5-year outcome and morbidity of three-dimensional conformai radiotherapy versus transperineal permanent iodine-125 implantation for early-stage cancer. J Clin Oncol 1999; 17:517-22.
68. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M et al. Health-related quality of life after permanent 1-125 brachytherapy and conformai external beam radiotherapy for prostate cancer-a matched-pair comparison. Radiother Oncol 2009;91:225-31.
69. Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009;55:227-36.
70. Pinkawa M, Piroth MD, Asadpour B, Gagel B, Fischedick K, Siluschek J et al. Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. A quality-of-life analysis. Strahlenther Onkol 2009;185:101-8.
71. Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2009;75:1344-9.
72. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007;25:5366-73. (Pubitemid 350232211)
73. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006;66:647-53.
74. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, CanbyHagino E et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007;25:2225-9. (Pubitemid 46954647)
75. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: eortc 22911. J Clin Oncol 2007;25:4178-86. (Pubitemid 47548556)
76. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329-35. (Pubitemid 44749360)
77. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008;72:1298-302.
78. Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol 2008;174:2204-8.
79. Neuhof D, Hentschel T, BischofM, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformai salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys 2007;67:1411-7. (Pubitemid 46467172)
80. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007;69:54-61. (Pubitemid 47247505)
81. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2007;291:1325-32.
82. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41. (Pubitemid 46972788)
83. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9.
84. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE et al. Salvage radiotherapy for men with isolated rising psa or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004;64:760-4.
85. King CR, Kapp DS, King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 2008;71:346-50.
86. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI et al. Suspected local recurrence after radical prostatectomy: endorectal coil mr imaging. Radiology 2004;231:379-85. (Pubitemid 38552892)
87. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H et al. 18F-choline and/or ' 'C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostatespecific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007;99:1415-20. (Pubitemid 47164795)
88. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med 2002;29:1380-4. (Pubitemid 44392221)
89. Seppälä J, Seppänen M, Arponen E, Lindholm P, Minn H. Carbon11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009;93:234-40.
90. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-8. (Pubitemid 46630746)
91. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80. (Pubitemid 350166735)
92. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the eortc radiation oncology group. Radiother Oncol 2007;84:121-7. (Pubitemid 47284534)
93. Pinkawa M, Siluschek J, Gagel B, Piroth MD, Demirel C, Asadpour B et al. Postoperative radiotherapy for prostate cancer : evaluation of target motion and treatment techniques (intensity-modulated verjus conformai radiotherapy). Strahlenther Onkol 2007; 183:23-9. (Pubitemid 46144102)
94. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Holy R et al. Health-related quality of life after adjuvant and salage postoperative radiotherapy for prostate cancer - a prospective analysis. Radiother Oncol 2008;88:135-139. (Pubitemid 351888892)
95. Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67:1106-12.
96. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112:1247-53. (Pubitemid 351429739)
97. Din OS, Thanvi N, Ferguson C, Kirkbride P. Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol2009;93:192-6.
98. Zelefsky M, Scher HI, Forman J, Linares LA, Curley T, Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys 1989;17:1281-5. (Pubitemid 20028647)
99. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25:1423-36. (Pubitemid 46706892)
100. Rades D, Stalpers LJ, Veninga T, Rudat V, Schulte R, Hoskin PJ. Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. J Urol 2006; 175:552-6. (Pubitemid 43067351)